Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 6, Number 6—December 2000
Perspective

Evidence Against Rapid Emergence of Praziquantel Resistance in Schistosoma haematobium, Kenya

Charles H. King*, Eric M. Muchiri†, and John H. Ouma†
Author affiliations: *Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio, USA; †Ministry of Health, Nairobi, Kenya

Main Article

Figure 2

Efficacy of praziquantel therapy for Schistosoma haematobium according to prior treatment status. Solid bars indicate yearly cure rates for patients receiving their first praziquantel treatment. Hatched bars indicate cure rates for children with a history of prior praziquantel treatment. No significant differences in efficacy were noted in any of the years studied (1985-1991).

Figure 2. Efficacy of praziquantel therapy for Schistosoma haematobium according to prior treatment status. Solid bars indicate yearly cure rates for patients receiving their first praziquantel treatment. Hatched bars indicate cure rates for children with a history of prior praziquantel treatment. No significant differences in efficacy were noted in any of the years studied (1985-1991).

Main Article

Page created: December 17, 2010
Page updated: December 17, 2010
Page reviewed: December 17, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external